| Denne siden krever at du er innlogget. Logg deg inn ved å angi ditt personlige brukernavn og passord eller ved bruk av PIN kode | |
 Søk om brukernavn og passord Har du glemt ditt brukernavnog passord? |
|
|
Dokument: Diabetes typ II A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyIncretin mimetics are an emerging class of compounds that have the ability to improve glycaemic control through multiple antihyperglycaemic actions similar to natural incretin hormones Åpne dokumentetDokument: Diabetes typ II Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.Exenatide, an incretin mimetic for adjunctive treatment of type 2 diabetes (T2DM), reduced hemoglobin A1c (A1C) and weight in clinical trials. Åpne dokumentetDokument: Produkter Amigo - DeFronzo Met Diabetes Care ReprintEffects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Åpne dokumentetDokument: Produkter Amigo - Kendall Met Sfu Diabetes Care ReprintEffects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Åpne dokumentetDokument: Produkter Amigo - Buse Sfu Diabetes Care ReprintEffects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Åpne dokumentet |
